Carbohydrate-based Antidiabetic Glycomedicine Development

CD BioGlyco is a world-leading independent biotechnology company, focusing on high-quality innovative services related to glycobiology. CD BioGlyco has professional glycomedicine development teams with multiple world-leading technologies to help customers comprehensively promote the development of carbohydrate-based antidiabetic glycomedicine.

Diabetes Mellitus and Antidiabetic Agents

The incidence of diabetes (DM) is increasing rapidly. More than 90% of these cases are type 1 diabetes mellitus (T2DM), and the remaining types include type 1 diabetes mellitus (T1DM) and hybrid forms of diabetes. Effective control of blood glucose is the basis of treatment for all patients with diabetes. While T1DM patients need lifelong insulin replacement therapy, for some T2DM patients, especially whose β-cells remain certain insulin-secreting function, oral hypoglycemic agents (OADs) can be used. Since blood glucose is a major driving factor of diabetes, glucose-based molecules have been extensively studied for diabetes treatment.

Presently, there are several antidiabetic drugs used to treat or manage diabetes and the mechanisms of action of these drugs are well known. These include the inhibition of α-amylase, α-glucosidase, lipase, and dipeptidyl peptidase IV (DPP-IV). Therefore, the development of carbohydrate-based antidiabetic glycomedicine acting on these two inhibitors has received increasing attention.

Fig 1. The development of beta-Klotho-based drugs with anti-diabetic effect.Fig.1 The development of β-Klotho-based drugs with anti-diabetic effect. (Bettini, et al., 2020)

Carbohydrate-based Antidiabetic Glycomedicine Services

As a leading platform provider in carbohydrate-based glycomedicine development, CD BioGlyco has various systematic services for in vitro and in vivo antidiabetic activity assay including enzyme activity assay and analysis of blood glucose levels. Our services include but are not limited to α-amylase inhibitory assay, analysis of blood glucose levels, α-glucosidase inhibitory assay, lipase inhibition assays and DPP-IV inhibition assay.

Advantages of Us

  • Experienced and well-trained technicians.
  • Efficient activity measurement method.
  • A comprehensive and advanced platform.
  • Detailed and reliable after-sales service.
  • Optimal experimental conditions.

At CD BioGlyco, we will work with our customers to define specific requirements and expectations to meet the partnership objectives. CD BioGlyco aspires to become the trusted solution provider of your first choice. Our professional research teams provide customers with high-quality carbohydrate-based antidiabetic glycomedicine development services according to their needs. For further details, please don't hesitate to contact us.

Reference:

  1. Bettini S.; et al. Reviews in endocrine and metabolic disorders. Reviews in Endocrine & Metabolic Disorders, 2020, 21(3): 297-306.
This service is for Research Use Only, not intended for any clinical use.

Christmas

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.